<DOC>
	<DOCNO>NCT00887757</DOCNO>
	<brief_summary>This Phase 1 open-label study evaluate safety navitoclax ( ABT-263 ) combine standard regimen gemcitabine approximately 50 subject solid tumor measurable disease .</brief_summary>
	<brief_title>Safety Study ABT-263 Combination With Gemzar ( Gemcitabine ) Subjects With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Navitoclax</mesh_term>
	<criteria>Inclusion Criteria Age great equal 18 year . For 21 28day dose escalation cohort 21day safety expansion cohort subject must histologically and/or cytologically documented cancer gemcitabine determine appropriate therapy , per Investigator . For 28day safety expansion cohort , subject must histologically and/or cytologically document ductal adenocarcinoma undifferentiated carcinoma pancreas gemcitabine determine appropriate firstline therapy , per investigator . Note : If 28day dose escalation schedule deem intolerable dose deescalation explore , expand safety cohort evaluate navitoclax ( ABT263 ) combination gemcitabine additional 12 15 subject histologically ductal adenocarcinoma undifferentiated carcinoma pancreas gemcitabine determine appropriate firstline therapy RPTD schedule 21day portion study . Measurable disease CT MRI define RECIST . Subjects brain metastasis must clinically control neurologic symptom , define surgical excision and/or radiation therapy follow 21 day stable neurologic function evidence CNS disease progression determine CT MRI within 28 day prior 1st dose study drug . ECOG le equal 1 . Must adequate bone marrow , renal hepatic function per local laboratory reference range follow : Bone marrow : Absolute Neutrophil Count great equal to1500/μL ; platelet great equal 150,000/mm^3 ; hemoglobin great equal 9.0 g/dL ; Renal function : Serum creatinine less equal 2.0 mg/dL calculate creatinine clearance great equal 50 mL/min ; Hepatic function enzyme : AST , ALP ALT less equal 3.0 × upper limit normal ( ULN ) , bilirubin less equal 1.5 × ULN . Subjects liver metastasis may AST , ALP , ALT le equal 5.0 X ULN . Subjects bone metastasis may ALP less equal 5.0 × ULN ; Coagulation : aPTT PT exceed 1.2 × ULN . Female subject must surgically sterile , postmenopausal ( least 1 year ) , negative result pregnancy test perform follow : Screening via serum sample obtain within 14 day prior initial study drug administration prior dose via urine sample obtain Cycle 1 Day 1 , great 7 day since obtain serum pregnancy test result . Female subject surgically sterile postmenopausal ( least 1 year ) nonvasectomized male subject must practice least 1 follow method birth control : total abstinence sexual intercourse ( minimum 1 complete menstrual cycle ) ; vasectomize partner ; hormonal contraceptive ( oral , parenteral transdermal ) least 3 month prior study drug administration ; Doublebarrier method ( include condom , contraceptive sponge , diaphragm vaginal ring spermicidal jelly cream ) . Exclusion Criteria Underlying , predispose condition bleed currently exhibit sign bleed . Recent history thrombocytopenia associate bleed w/i 1 year prior 1st dose study drug . Currently receive require anticoagulation therapy drug herbal supplement affect platelet function , w/the exception lowdose anticoagulation medication use maintain patency central iv catheter . Active peptic ulcer disease potentially hemorrhagic esophagitis/gastritis . Active immune thrombocytopenic purpura , autoimmune hemolytic anemia history refractory platelet transfusion ( w/i 1 year prior 1st dose study drug ) . Received radioimmunotherapy w/i 6 month prior 1st dose study drug . Received antibody therapy biologics ( exception colony stimulate factor [ GCSF , GMCSF ] erythropoietin ) w/i 28 day prior 1st dose study drug . Received anticancer therapy include chemotherapy , immunotherapy , radiotherapy , hormonal therapy ( exception hormone hypothyroidism , ERT , antiestrogen analog , LHRH , GnRH agonists require suppress serum testosterone level stable dose least 21 day prior 1st dose study drug ) , investigational therapy w/i 14 day prior 1st dose study drug , recover less grade 2 clinically significant adverse effect ( ) / toxicity ( ) previous therapy . Received steroid therapy antineoplastic intent w/i 7 day prior 1st dose study drug . ( Inhaled steroid asthma , topical steroid , replacement/stress corticosteroid , corticosteroid take premedication study consider exclusionary ) . Received aspirin w/i 7 day prior 1st dose study drug . History hypersensitivity gemcitabine.Positive HIV . Significant history cardiac , renal , neurologic , psychiatric , endocrinologic , metabolic , immunologic , hepatic disease . Exhibits evidence clinically significant uncontrolled condition ; active systemic fungal infection ; diagnosis fever &amp; neutropenia w/i 1 week prior study drug administration . The subject undergone prior procedure active gastrointestinal disease would result inability adequately absorb oral medication ( e.g. , uncontrolled nausea , vomit , inflammatory disease , bowel obstruction , major bowel resection ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>